Study of the Effects of Adolescent Weight Disorders (Obesity, Anorexia Nervosa) on Heart Function
NCT ID: NCT05071157
Last Updated: 2023-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
87 participants
OBSERVATIONAL
2019-03-06
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To meet this objective, several analyzes are planned including a speckle tracking echocardiography, allowing a non-invasive study of myocardial deformations.
The hypothesis is that two opposite weight disorders (anorexia nervosa and obesity) lead to similar complications: inflammation, fibrosis altering the myocardial structure and therefore its contractility. Both systolic and diastolic dysfunction appear. Investigator hypothesize that the determinants of this dysfunction involve part of the alteration of body mass, and partly qualitative alterations specific to each pathology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Assessment in Obese and Overweight Children
NCT05371821
Cohort of Heart Failure Patients
NCT03422991
Classification of Heart Failure in Children
NCT03451097
Interval Training in Heart Failure
NCT03955029
Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol Levels
NCT07178444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The search for the mechanisms at the origin of these alterations represents our secondary objective. For this, a correlation of the cardiac parameters with several factors such as: duration and severity of disorders, body composition, heart mass, presence of myocardial fibrosis, epicardial fat level, sympatho-vagal balance (by the cardiac variability), systemic inflammatory profile and potential pathways signaling involved (metabolomic analysis) will be carried out. All these parameters may impact cardiac function.
Adolescent girls participating in the study will benefit from a clinical examination with fat / lean body mass measurement by impedance, assessment of heart rate variability, blood test (inflammation marker, metabolomic analysis) and ultrasound heart. Thus, screening for heart disease, and more generally complications of their pathology, will be performed.
This project is important to answer the question of the necessity or not of a systematic cardiac assessment in these adolescents and the setting up of an adapted care
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
anorexia nervosa
girls between 12 and 18 years old with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
echocardiography
* speckle tracking echocardiography
* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)
* bioimpedance
* blood test for biological assays (metabolomic analysis)
obesity
girls between 12 and 18 years old with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30).
echocardiography
* speckle tracking echocardiography
* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)
* bioimpedance
* blood test for biological assays (metabolomic analysis)
normal weight
girls between 12 and 18 years old without BMI abnormality, without eating disorders, without serious medical pathology
echocardiography
* speckle tracking echocardiography
* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)
* bioimpedance
* blood test for biological assays (metabolomic analysis)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
echocardiography
* speckle tracking echocardiography
* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)
* bioimpedance
* blood test for biological assays (metabolomic analysis)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
* or, with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30)
* or, without BMI abnormality, without eating disorders, without serious medical pathology
Exclusion Criteria
* for the obese, secondary obesity
* for all, inability to provide informed consent, pregnancy or breastfeeding, heart disease, high blood pressure, sleep apnea syndrome, dyslipidemia, diabetes, chronic pathology including inflammatory.
12 Years
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Justine Paysal
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU clermont-ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A01907-48
Identifier Type: OTHER
Identifier Source: secondary_id
RBHP 2018 PAYSAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.